Crossmark

Evaluating a novel approach to placenta accreta spectrum management: the modified Triple-P technique with cystoinflation (a randomized controlled trial)

Crossref DOI link: https://doi.org/10.1038/s41598-025-07582-6

Published Online: 2025-07-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Saaqib, Shazia https://orcid.org/0000-0003-4667-3350
Naheed, Munazza

Iqbal, Ayesha

Rehman, Rana Muhammad Armughan Ur

Khalid, Mohammad
Funding

Funding for this research was provided by:

No funding ws required for this study.All medicines were available in hospital free of cost
License Information

Text and Data Mining valid from 2025-07-16

Version of Record valid from 2025-07-16
More Information

Article History

Received: 3 April 2025

Accepted: 16 June 2025

First Online: 16 July 2025

Declarations

:

: The authors declare no competing interests.

: This randomized controlled trial was conducted as part of the Cystoinflation project, and received ethical approval from the Ethical Review Committee of King Edward Medical University (KEMU), Pakistan (IRB #216/RC/KEMU, March 27, 2017). It was later registered retrospectively in ClinicalTrials.gov (Reg#NCT04302545, March 10, 2020), a primary registry recognized by the WHO International Clinical Trials Registry Platform.

Document is current

Any future updates will be listed below